Metastatic Castration-Resistant Prostate Cancer (mCRPC)
"The Prostate Cancer Research Institute, (PCRI), a 501(c)(3) not-for-profit organization, mission is to improve the quality of prostate cancer patients and caregivers lives by supporting research and disseminating information that educates and empowers patients, families and the medical community."
Researchers are hopeful about the potential for a novel agent in high-risk prostate cancer.
Patients treated with Xtandi had higher rates of fatigue and pain than those who were treated with Zytiga and prednisone, resulting in a higher likelihood that they will reduce their treatment dose.
This research was presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of over 30,000 oncology professionals in Chicago.
Patients with early-stage prostate cancer may be able to shorten their radiation time, thanks to the results of a recent study conducted by the Duke Cancer Institute.
A life-saving therapy for patients with prostate cancer may cause clinical depression, according to a recent study.
Several new tests for prostate cancer are on the market. When used alongside PSA screenings, they can provide a much more straightforward insight into prostate cancer risk.
It is crucial to know all the side effects of the medication and surgeries you receive before starting cancer treatment.
As medical advances continue, the Prostate Cancer Foundation is determined to find a cure for the disease.
Through Malecare, men are coming together to fight prostate cancer.
Many advances have been made in the fight against prostate cancer in the past two decades, but ZERO will not stop until the disease is completely ended.
Choosing the right treatment option for prostate cancer can be overwhelming, and sometimes a lack of information or second opinion can lead to a wrong decision.
An essay from our Extraordinary Healers book honoring Sharon Bernico, RN, OCN [Oncology Therapy Center in Morris, Illinois].
The designation is based on data from the phase 2 TOPARP-A trial that demonstrated that Lynparza monotherapy had an overall response rate of nearly 90 percent in a biomarker-defined subgroup of patients who had DNA-repair defects.
A legendary cornerback in the NFL, former New England Patriots and Los Angeles Raiders star Mike Haynes is no stranger to going to battle on the gridiron.
Despite the fact that it has been three years since the drug was approved by the FDA, many oncologists still need to be educated regarding Xofigo's benefits beyond pain palliation,
Among undiagnosed men who took regular aspirin, the risk of developing a lethal form of prostate cancer was reduced by 24 percent.
Men with prostate cancer may be eligible to join a patient registry that will track their treatment choices and outcomes, as well as quality-of-life measures and the health of their caregivers over time.
When diagnosing prostate cancer, doctors consider staging and grading. In grading, a score is assigned based on the Gleason grading system.
Understanding state-of-the-art care helps patients with prostate cancer to choose treatments
New advances in radiation treatment enable higher doses with less damage to nearby tissue.
Medical and scientific communities continue to weigh the value of PSA screening
BRCA mutations can lead to prostate and other cancers, and men are as likely as women to inherit them. Yet male awareness is lagging.
